SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cadila Healthcare’s arm gets USFDA’s approval for Pramipexole Dihydrochloride Tablets

14 Dec 2017 Evaluate

Cadila Healthcare’s wholly owned subsidiary Zydus Pharmaceuticals (USA) Inc. has received the final approval from the United States Food & Drug Administration (USFDA) to market Pramipexole Dihydrochloride Extended-Release Tablets in strengths of 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg, 3.75 mg and 4.5 mg. The drug is indicated to treat signs and symptoms of Parkinson's disease (PD).

The group also received the final approval from the USFDA to market Nitrofurantoin Capsules USP (macrocrystals), 50 mg and 100 mg, which is indicated to treat acute uncomplicated urinary tract infections. Both the drugs will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

The group now has more than 175 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

939.00 -3.55 (-0.38%)
20-Apr-2026 13:32 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.80
Dr. Reddys Lab 1236.00
Cipla 1233.30
Zydus Lifesciences 939.00
Lupin 2331.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×